NVS [NYSE]
Novartis AG
Index- P/E7.45 EPS (ttm)10.21 Insider Own9.30% Shs Outstand2.20B Perf Week-5.75%
Market Cap186.75B Forward P/E11.38 EPS next Y6.68 Insider Trans0.00% Shs Float2.18B Perf Month-9.09%
Income22.98B PEG1.80 EPS next Q1.56 Inst Own9.20% Short Float0.26% Perf Quarter-10.40%
Sales52.79B P/S3.54 EPS this Y202.30% Inst Trans-3.91% Short Ratio2.64 Perf Half Y-12.27%
Book/sh28.63 P/B2.65 EPS next Y9.44% ROA18.30% Target Price102.00 Perf Year-9.05%
Cash/sh8.04 P/C9.45 EPS next 5Y4.14% ROE36.90% 52W Range75.53 - 94.26 Perf YTD-13.10%
Dividend3.33 P/FCF34.70 EPS past 5Y30.60% ROI9.70% 52W High-21.17% Beta0.54
Dividend %4.37% Quick Ratio1.10 Sales past 5Y1.40% Gross Margin70.90% 52W Low-1.62% ATR1.30
Employees108000 Current Ratio1.40 Sales Q/Q-1.60% Oper. Margin20.60% RSI (14)21.20 Volatility1.40% 1.38%
OptionableYes Debt/Eq0.49 EPS Q/Q-40.70% Profit Margin43.50% Rel Volume1.10 Prev Close76.01
ShortableYes LT Debt/Eq0.38 EarningsJul 19 BMO Payout31.10% Avg Volume2.15M Price74.31
Recom2.20 SMA20-7.68% SMA50-10.94% SMA200-13.47% Volume1,619,406 Change-2.24%
Sep-15-22Downgrade Credit Suisse Neutral → Underperform
Sep-14-22Downgrade Berenberg Buy → Hold
May-09-22Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-22Resumed Citigroup Buy
Dec-14-21Downgrade Redburn Buy → Neutral
Dec-06-21Downgrade Exane BNP Paribas Outperform → Neutral
Dec-03-21Downgrade Bryan Garnier Buy → Neutral
Sep-20-21Downgrade Deutsche Bank Hold → Sell
Mar-22-21Initiated Bernstein Mkt Perform
Mar-10-21Downgrade Argus Buy → Hold
Feb-01-21Downgrade Cowen Outperform → Market Perform $110 → $105
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Buy
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Sep-26-22 09:03AM
09:00AM
Sep-23-22 02:26PM
10:07AM
08:58AM
02:57AM
Sep-22-22 11:04AM
06:22AM
02:13AM
01:42AM
01:15AM
Sep-21-22 10:02AM
08:45AM
07:41AM
02:35AM
01:27AM
01:00AM
Sep-20-22 09:53PM
11:12AM
Sep-19-22 06:43AM
01:15AM
Sep-18-22 10:45AM
Sep-16-22 09:58AM
Sep-15-22 08:00AM
07:06AM
02:34AM
01:30AM
01:15AM
12:05AM
Sep-14-22 11:35PM
02:05PM
Sep-12-22 11:11AM
10:43AM
Sep-10-22 02:30AM
Sep-09-22 08:38AM
07:50AM
07:31AM
01:15AM
Sep-02-22 01:15AM
Sep-01-22 10:41AM
07:43AM
01:17AM
01:00AM
Aug-30-22 12:17PM
01:15AM
Aug-29-22 07:49AM
07:43AM
Aug-26-22 06:25PM
01:35PM
01:17PM
09:09AM
01:03AM
Aug-25-22 04:48PM
11:44AM
10:31AM
10:12AM
10:07AM
09:49AM
07:33AM
06:35AM
06:30AM
05:27AM
05:21AM
01:53AM
01:23AM
01:00AM
12:01AM
Aug-23-22 11:28AM
Aug-19-22 09:07AM
Aug-18-22 02:14PM
Aug-16-22 12:00PM
Aug-15-22 10:05AM
07:17AM
04:23AM
01:15AM
Aug-12-22 11:14AM
Aug-11-22 05:28PM
Aug-10-22 08:14AM
Aug-02-22 11:47AM
11:00AM
Aug-01-22 09:13AM
08:04AM
Jul-29-22 02:04PM
11:01AM
Jul-28-22 10:15AM
Jul-26-22 04:42PM
10:09AM
Jul-25-22 06:21AM
01:15AM
Jul-22-22 08:22AM
06:49AM
Jul-21-22 10:40AM
10:15AM
01:15AM
Jul-20-22 09:17AM
08:32AM
Jul-19-22 05:00PM
04:07PM
10:37AM
06:58AM
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.